Ask AI

Major Depressive Disorder Across the Lifespan: Practical Pearls From General, Pediatric, and Geriatric Psychiatry

Video
This activity is available for 1.50 CME/CE credit(s).

Released: November 05, 2026

Expiration: November 04, 2027

See Activity Collection

From irritability and school difficulties in adolescents to persistent anhedonia in adults and cognitive complaints in older patients, major depressive disorder presents unique challenges across the lifespan. This on-demand webcast explores age-specific screening, antidepressant selection, switching and augmentation strategies, and the efficacy and safety considerations that guide adjunctive treatment decisions across different stages of life.

MDD Across the Lifespan

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with MDD do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 16-yr-old patient with MDD continues to experience significant depressive symptoms despite an adequate 8-wk trial of fluoxetine with confirmed adherence. The patient has not received psychotherapy, and no immediate safety concerns are identified.

Which treatment strategy would you use next?

4.

A 47-yr-old patient with MDD has experienced a partial response to an adequately dosed antidepressant but continues to report anhedonia and difficulty concentrating. The patient has obesity and prediabetes, and a previous trial of aripiprazole caused intolerable akathisia.

Which FDA-approved adjunctive treatment is most appropriate to consider?

5.

A 73-yr-old patient with MDD continues to experience fatigue, difficulty concentrating, and reduced social engagement despite antidepressant treatment. Family members report increasing memory difficulties and express concern about dementia.

What is the most appropriate next step?